Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 3Lung Neoplasms 3Esophageal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Solid Tumor, Adult 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Endometrial Neoplasms 1Breast Cancer Metastatic 1

Interventions

pembrolizumab 2toripalimab 1tislelizumab 1spartalizumab 1peposertib 1pazopanib 1patritumab deruxtecan 1palbociclib 1osimertinib 1lenvatinib 1atezolizumab 1amivantamab 1Tiragolumab 1Cryosurgery 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Solid Tumor, Adult × patritumab deruxtecan × Clear all
NCT06383884 2025-12-15

Patritumab Deruxtecan in Patients With Solid Tumor Harboring an NRG1 Fusion

Samsung Medical Center

Phase 2 Recruiting
30 enrolled
Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡